IPR decision (Jan 11, 2018):
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent No.
|
Status
|
|
IPR2016-00084
|
10/26/2015
|
04/29/2016
|
Par Pharmaceutical, Inc.
|
US 5,665,772
|
Final Written Decision (claims 1–3 and 8–10 are patentable)
|
Roxane, Breckenridge IPRs (IPR2016-01102 & IPR2016-01023) were terminated as they joined above IPR & Par, Breckenridge’s IPRs (IPR2016-01059 & IPR2016-01103) were denied.
US 5,665,772 patent claims compound.
Leave a Reply